G
Geoff Hall
Researcher at University of Leeds
Publications - 67
Citations - 1794
Geoff Hall is an academic researcher from University of Leeds. The author has contributed to research in topics: Cancer & Ovarian cancer. The author has an hindex of 18, co-authored 60 publications receiving 1184 citations. Previous affiliations of Geoff Hall include St James's University Hospital & Leeds Teaching Hospitals NHS Trust.
Papers
More filters
Journal ArticleDOI
Copy number signatures and mutational processes in ovarian carcinoma
Geoff Macintyre,Teodora Goranova,D.G.H. de Silva,Darren Ennis,Anna M. Piskorz,Matthew D. Eldridge,Daoud Sie,Liz Anne Lewsley,Aishah Hanif,Cheryl Wilson,Suzanne Dowson,Rosalind Glasspool,Michelle Lockley,Michelle Lockley,Elly Brockbank,Ana Montes,Axel Walther,Sudha Sundar,Richard J. Edmondson,Richard J. Edmondson,Geoff Hall,Andrew R Clamp,Charlie Gourley,Marcia Hall,Christina Fotopoulou,Hani Gabra,Hani Gabra,James Paul,Anna Supernat,David Millan,Aoisha Hoyle,Gareth Bryson,Craig Nourse,Laura Mincarelli,Luis Navarro Sanchez,Bauke Ylstra,Mercedes Jimenez-Linan,Luiza Moore,Oliver Hofmann,Oliver Hofmann,Florian Markowetz,Iain A. McNeish,Iain A. McNeish,Iain A. McNeish,James D. Brenton +44 more
TL;DR: It is shown that HGSOC comprises a continuum of genomes shaped by multiple mutational processes that result in known patterns of genomic aberration, and copy number signature exposures at diagnosis predict both overall survival and the probability of platinum-resistant relapse.
Journal ArticleDOI
Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study.
Alvina G. Lai,Laura Pasea,Amitava Banerjee,Amitava Banerjee,Geoff Hall,Geoff Hall,Spiros Denaxas,Wai Hoong Chang,Michail Katsoulis,Bryan Williams,Deenan Pillay,Mahdad Noursadeghi,David C. Linch,Derralynn Hughes,Martin Forster,Clare Turnbull,Natalie K Fitzpatrick,Kathryn Boyd,Graham R. Foster,Tariq Enver,Vahé Nafilyan,Ben Humberstone,Richard D Neal,Matt Cooper,Monica Jones,Kathy Pritchard-Jones,Richard Sullivan,C. A. Davie,Mark Lawler,Harry Hemingway +29 more
TL;DR: Dramatic reductions were detected in the demand for, and supply of, cancer services which have not fully recovered with lockdown easing and may contribute, over a 1-year time horizon, to substantial excess mortality among people with cancer and multimorbidity.
Posted ContentDOI
Estimating excess mortality in people with cancer and multimorbidity in the COVID-19 emergency
Alvina G. Lai,Laura Pasea,Amitava Banerjee,Amitava Banerjee,Spiros Denaxas,Michail Katsoulis,Wai Hoong Chang,Bryan Williams,Deenan Pillay,Mahdad Noursadeghi,David C. Linch,Derralynn Hughes,Martin Forster,Clare Turnbull,Natalie K Fitzpatrick,Kathryn Boyd,Graham R. Foster,Mark E. Cooper,Monica Jones,Kathy Pritchard-Jones,Richard Sullivan,Geoff Hall,C. A. Davie,Mark Lawler,Harry Hemingway +24 more
TL;DR: First estimates of potential excess mortality among people with cancer and multimorbidity due to the COVID-19 emergency are provided and there is an urgent need for weekly data on cause-specific excess mortality, cancer diagnosis and treatment provision and better intelligence on the use of effective treatments for comorbidities.
Journal ArticleDOI
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
Yvette Drew,Jonathan A. Ledermann,Geoff Hall,Daniel Rea,R.M. Glasspool,Martin Highley,Gordon C Jayson,Julieann Sludden,James W. Murray,David Jamieson,Sarah Halford,Gary Acton,Zoe Backholer,Raffaella Mangano,Alan V. Boddy,Nicola J. Curtin,Ruth Plummer +16 more
TL;DR: In this article, intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer were investigated.
Posted ContentDOI
Copy-number signatures and mutational processes in ovarian carcinoma
Geoff Macintyre,Teodora Goranova,D.G.H. de Silva,Darren Ennis,Anna M. Piskorz,Matthew D. Eldridge,Daoud Sie,Liz Anne Lewsley,Aishah Hanif,Cheryl Wilson,Suzanne Dowson,Rosalind Glasspool,Michelle Lockley,Elly Brockbank,Ana Montes,Axel Walther,Sudha Sundar,Richard J. Edmondson,Geoff Hall,Andrew R Clamp,Charlie Gourley,Marcia Hall,Christina Fotopoulou,Hani Gabra,James Paul,Anna Supernat,David Millan,Aoisha Hoyle,Gareth Bryson,Craig Nourse,Laura Mincarelli,Luis Navarro Sanchez,Bauke Ylstra,Mercedes Jimenez-Linan,Luiza Moore,Oliver Hofmann,Florian Markowetz,Iain A. McNeish,James D. Brenton +38 more
TL;DR: It is demonstrated that most tumours are heterogeneous and harbour multiple signature exposures, and changes in signature exposure observed in response to chemotherapy suggest potential treatment strategies.